Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 20;73(16):1273-9.
doi: 10.1212/WNL.0b013e3181bd1326.

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas

A Kim  1 , A Gillespie, E Dombi, A Goodwin, W Goodspeed, E Fox, F M Balis, B C Widemann
Affiliations

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas

A Kim et al. Neurology. .

Abstract

Objective: To describe the characteristics of children enrolled in treatment trials for neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN), PN tumor burden, PN-related complications, and treatment outcomes and to highlight the differences between characteristics of children with NF1 vs children with cancers entered on early phase drug trials.

Methods: Pre-enrollment characteristics and complications of PN were retrospectively analyzed in a cohort of 59 children with NF1-related PN treated on 1 of 7 clinical trials at the NIH between 1996 and 2007. Outcome was analyzed in a subset of 19 patients enrolled in phase I trials. Comparisons to children with cancer were made from a similar analysis performed recently.

Results: The median age at enrollment was 8 years. The median PN volume was 555 mL. Most patients had no prior chemotherapy or radiation, but nearly half had previous surgery for PN. PN-associated complications and NF1 manifestations were common, including pain (53%), other tumors (18%), and hypertension (8%). Investigational drug therapy was well tolerated. A median of 10 treatment cycles was administered. Patients with NF1-related PN were younger, had better performance score, had less prior therapy, and remained on study longer than cancer patients.

Conclusions: Children with NF1-related plexiform neurofibroma (PN) enrolled in clinical trials had large tumors with substantial morbidity. Clinical trials in these children provide information about drug tolerance, cumulative toxicity, and pharmacokinetics in a younger population than early phase pediatric cancer trials. This report may aid in the evaluation of the applicability of traditional pediatric cancer trial designs and endpoints for NF1-related PN.

PubMed Disclaimer

Figures

None
Figure Plexiform neurofibroma (PN) anatomic location A total of 87 PN were evaluated in 59 patients. A total of 23 patients had ≥2 PN. PN location: head (n = 6), head/neck (n = 8), neck/trunk (n = 5), trunk (n = 35), trunk/extremities (n = 21), extremity only (n = 3).
See this image and copyright information in PMC

References

    1. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999;89:31–37. - PubMed
    1. Needle MN, Cnaan A, Dattilo J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children’s Hospital of Philadelphia experience, 1974–1994. J Pediatr 1997;131:678–682. - PubMed
    1. Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 2007;68:643–647. - PubMed
    1. Packer RJ, Gutmann DH, Rubenstein A, et al. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002;58:1461–1470. - PubMed
    1. Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006;24:507–516. - PubMed

Publication types

MeSH terms

Substances